^
BIOMARKER:

IDH2 mutation

i
Other names: IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
Entrez ID:
Related biomarkers:
IDH2 mutation
AML
enasidenib
Sensitive: A1 - Approval
IDH2 mutation
AML
venetoclax
Sensitive: A2 - Guideline
IDH2 mutation
AML
cytarabine
Resistant: B - Late Trials
IDH2 mutation
Glioma
temozolomide
Sensitive: B - Late Trials
IDH2 mutation
Glioma
temozolomide gel
Sensitive: B - Late Trials
IDH2 mutation
Glioma
PCV
Sensitive: B - Late Trials
IDH2 mutation
AML
venetoclax + azacitidine
Sensitive: B - Late Trials
IDH2 mutation
Glioma
pamiparib
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
Cholangiocarcinoma
dasatinib
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
Leukemia
venetoclax
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
MDS
enasidenib
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
AML
MEN-1703
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
Glioma
AG-881
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
Glioma
TG02
Sensitive: C3 – Early Trials
IDH2 mutation
AML
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
IDH2 mutation
AML
venetoclax + enasidenib
Sensitive: C3 – Early Trials
IDH2 mutation
AML
venetoclax + RO5503781
Sensitive: C3 – Early Trials
IDH2 mutation
Peripheral T-cell Lymphoma
copanlisib
Sensitive: C3 – Early Trials
IDH2 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
IDH2 mutation
AML
venetoclax + ABBV-621
Sensitive: C3 – Early Trials
IDH2 mutation
AML
CFI-400945
Sensitive: C3 – Early Trials
IDH2 mutation
AML
venetoclax + midostaurin
Resistant: C3 – Early Trials
IDH2 mutation
AML
venetoclax + gilteritinib
Resistant: C3 – Early Trials
IDH2 mutation
AML
venetoclax + sorafenib
Resistant: C3 – Early Trials
IDH2 mutation
GBM
temozolomide gel
Sensitive: C3 – Early Trials
IDH2 mutation
T Cell Non-Hodgkin Lymphoma
lenalidomide
Resistant: C3 – Early Trials
IDH2 mutation
Anaplastic Astrocytoma
PCV
Sensitive: C3 – Early Trials
IDH2 mutation
Sarcoma
olaparib
Sensitive: C3 – Early Trials
IDH2 mutation
AML
7+3 (DAC)
Sensitive: C3 – Early Trials
IDH2 mutation
AML
cytarabine + clofarabine
Sensitive: C3 – Early Trials
IDH2 mutation
AML
cytarabine + cladribine
Sensitive: C3 – Early Trials
IDH2 mutation
AML
decitabine + clofarabine
Sensitive: C3 – Early Trials
IDH2 mutation
AML
decitabine + cladribine
Sensitive: C3 – Early Trials
IDH2 mutation
GBM
M7824
Sensitive: C3 – Early Trials
IDH2 mutation
AML
CDIAG
Sensitive: C3 – Early Trials
IDH2 mutation
Cholangiocarcinoma
AZD0530
Sensitive: D – Preclinical
IDH2 mutation
Cholangiocarcinoma
bosutinib
Sensitive: D – Preclinical
IDH2 mutation
Cholangiocarcinoma
ponatinib
Sensitive: D – Preclinical
IDH2 mutation
Glioma
APO866
Sensitive: D – Preclinical
IDH2 mutation
Glioma
NPI-0052
Sensitive: D – Preclinical
IDH2 mutation
Glioma
omacetaxine mepesuccinate
Sensitive: D – Preclinical
IDH2 mutation
Glioma
regorafenib
Sensitive: D – Preclinical
IDH2 mutation
Glioma
dactinomycin
Sensitive: D – Preclinical
IDH2 mutation
Glioma
romidepsin
Sensitive: D – Preclinical
IDH2 mutation
Glioma
daunorubicin
Sensitive: D – Preclinical
IDH2 mutation
Glioma
teniposide
Sensitive: D – Preclinical
IDH2 mutation
Glioma
gemcitabine
Sensitive: D – Preclinical
IDH2 mutation
Glioma
paclitaxel
Sensitive: D – Preclinical